2018, Volume 25, Supplement 1: Anticoagulation in atrial fibrillation: focus on PIONEER AF-PCI and its implications

Introduction

August 2018 Br J Cardiol 2018;25(suppl 1):S3–S5

Introduction

Patients with atrial fibrillation are at an increased risk for ischaemic stroke and require long-term prophylaxis with an anticoagulant. Ablation and direct current cardioversion are...
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI

August 2018 Br J Cardiol 2018;25(suppl 1):S6–S11

Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI

The PIONEER AF-PCI trial was an open-label, randomised, controlled, multi-centre trial that evaluated the safety of two different regimens of rivaroxaban compared with vitamin K...
The PIONEER AF-PCI study: its implications for everyday practice in the UK

August 2018 Br J Cardiol 2018;25(suppl 1):S12–S15

The PIONEER AF-PCI study: its implications for everyday practice in the UK

Our ageing population is resulting in increasing rates of coronary artery disease and atrial fibrillation (AF), which require intervention. Anticoagulation in patients with non-valvular AF...
The potential for NOACs in cardiac ablation in the UK

August 2018 Br J Cardiol 2018;25(suppl 1):S16–S17

The potential for NOACs in cardiac ablation in the UK

The procedural and post-procedure risk of stroke associated with catheter ablation of atrial fibrillation (AF), even in patients with low CHA2DS2-VASc scores, highlight the need...
Use of NOAC drugs in DC cardioversion for patients with non-valvular AF

August 2018 Br J Cardiol 2018;25(suppl 1):S18–S20

Use of NOAC drugs in DC cardioversion for patients with non-valvular AF

Direct current cardioversion (DCCV) is a frequently used and effective strategy for the restoration of sinus rhythm in patients with atrial fibrillation (AF). Anticoagulation for...